CryoLife's CryoValve^® SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft^® Technology, is indicated for the replacement of diseased, damaged, malformed or malfunctioning native pulmonary valves in pediatric and adult patients. The valve can be used in conjunction with right ventricular outflow tract reconstruction procedures (RVOT), and for pulmonary valve replacement during the Ross Procedure.

CryoLife markets BioGlue^®, an innovative biosurgical adhesive that is approved in the U.S. for use in adult patients as an adjunct to standard methods, such as sutures and staples, to help control bleeding in open surgical repair of large vessels. It is approved in the European Community, Canada and Australia as an adjunct to surgical repair for soft tissues such as vascular, cardiac, dura, pulmonary, and gastrointestinal. BioGlue is approved in over 50 countries.

CryoLife distributes Hemostase MPH, a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the United Kingdom and Germany for cardiac, vascular and general surgery, subject to certain exclusions. Hemostase MPH is developed using Medafor's Microporous Polysaccharide Hemospheres technology (MPH^®), which yields a plant-based, flowable powder engineered to rapidly dehydrate blood, enhancing clotting on contact. When used as directed, this highly effective hemostatic agent facilitates the formation of a resilient, natural clot within just a few minutes.

The company's R&D efforts are focused on protein hydrogel technologies (BioDisc^® for spinal repair and BioFoam^® for vascular and wound healing), SynerGraft^® antigen reduction technologies (cardiac, vascular and other soft tissues), including ProPatchÔ Soft Tissue Repair Matrix for rotator cuff and hernia repair, and transport solutions for the preservation of whole organs for transplantation.